Eric Jia-Sobota, Founder, Author at EverGlade Consulting

Eric Jia-Sobota, Founder

Eric Jia-Sobota is the National Leader of EverGlade’s Consulting Practice and the Founder of the Company. Eric’s consulting experience spans almost two decades across a breadth of industries, including, Federal Contracting, Life Sciences, Nonprofit, Technology, Construction, Healthcare, and others. View Eric's resume at https://ericjia-sobota.com/

Eric Jia-Sobota
Targeting Cancer Cells

EverGlade Consulting Helps SonALAsense Secure up to $46 Million in ARPA-H Funding

Leave a Comment / EverGlade Insights / By

EverGlade Consulting, a national consulting firm, has helped SonALAsense successfully secure up to $46 million in funding to develop a minimally or non-invasive ultrasound treatment to activate a compound that can destroy cancer cells. Improving Patient Outcomes The $46 million in ARPA-H funding, announced as part of ARPA-H’s initiative to revolutionize cancer treatment through cutting-edge […]

EverGlade Consulting Helps SonALAsense Secure up to $46 Million in ARPA-H Funding Read More »

EverGlade Consulting

EverGlade Consulting Continues Growth with Addition of Nathan Clark

Leave a Comment / EverGlade Insights / By

EverGlade Consulting, is pleased to announce the appointment of Nathan Clark as Director, effective November 2024. Mr. Clark brings an extensive background in government contracting and federal funding management, making him a valuable addition to the EverGlade team. Nathan Clark joins EverGlade Consulting with an impressive portfolio, having recently served as the BARDA portfolio leader

EverGlade Consulting Continues Growth with Addition of Nathan Clark Read More »

nucleic acid-based therapeutics

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis

Leave a Comment / BARDA, EverGlade Insights / By

PrEP_Solicitation_Nucleic_Acid_Platform_Approaches Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), partnered with the Vaccine Innovation and Therapeutics Accelerator Launchpad (VITAL), have announced a solicitation for proposals to address current limitations of long-acting nucleic acid-based platforms used as pre-exposure prophylaxis (PrEP) for seasonal respiratory viruses. The specific goals of these PrEP DEV awards include

BARDA Announces Solicitation to Improve Nucleic Acid Platforms for Pre-Exposure Prophylaxis Read More »

biologics

BARDA Issues RPP for On-Demand Manufacturing

Leave a Comment / BARDA, EverGlade Insights / By

RPP-24-02-ODM The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at the preparation for and response to public health emergencies through On-Demand Manufacturing. The RPP, numbered 24-02-ODM, focuses advancing manufacturing technologies that will improve access and enable faster, cheaper, more rapid, and flexible production of vaccines

BARDA Issues RPP for On-Demand Manufacturing Read More »

A closeup shot of a scientist conducting the gel electrophoresis biological process as part of coronavirus research

BARDA Announces Request for Project Proposals for Small Molecule Drugs

Leave a Comment / BARDA, EverGlade Insights / By

BARDA RRPV 24-03-SmMol The Biomedical Advanced Research and Development Authority (BARDA) has released a Request for Project Proposals (RPP) under the Rapid Response Partnership Vehicle (RRPV) for developing small molecule therapeutics aimed at COVID-19 Pre-exposure Prophylaxis (PrEP). This initiative enhances national health security by advancing medical countermeasures against SARS-CoV-2 and future health threats. BARDA’s call

BARDA Announces Request for Project Proposals for Small Molecule Drugs Read More »

Filovirus Monoclonal Antibodies

BARDA Announces RPP for Manufacturing Optimization for Filovirus Monoclonal Antibodies

Leave a Comment / BARDA, EverGlade Insights, Time Sensitive / By

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Request for Project Proposals (RPP) for “Manufacturing Optimization for Filovirus Monoclonal Antibodies.” The RPP was released on June 24, 2024, with proposals due by July 22, 2024. This initiative aims to enhance the manufacturing development of monoclonal antibody (mAb) cocktails targeting filoviruses like Ebola and Marburg viruses.

BARDA Announces RPP for Manufacturing Optimization for Filovirus Monoclonal Antibodies Read More »

African American woman in a technically advanced career

ARPA-H Announces Small Business Opportunities

Leave a Comment / ARPA-H, EverGlade Insights / By

The Advanced Research Projects Agency for Health (ARPA-H) has announced an upcoming solicitation for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) contracts for FY2024. The initiative targets innovative firms capable of conducting cutting-edge research and development, with a focus on commercializing the results. The solicitation includes opportunities for Phase I, Direct to Phase II, and Fast Track contracts.

ARPA-H Announces Small Business Opportunities Read More »

Abstract virus on blue background

BARDA Announces Request for Project Proposal to Establish Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services

Leave a Comment / BARDA, EverGlade Insights / By

Biomedical Advanced Research and Development Authority (BARDA) through the Rapid Response Partnership Vehicle (RRPV) initiative released a Request for Project Proposals (RPP) to establish Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services to support vaccine development and response to pandemics and emerging infectious diseases.

BARDA Announces Request for Project Proposal to Establish Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services Read More »

DARPA’s B-SAFE Industry Day

Join DARPA’s B-SAFE Industry Day for Groundbreaking Advances in Gene Editing Inhibitors

Leave a Comment / DARPA, EverGlade Insights, Time Sensitive / By

The Defense Advanced Research Projects Agency is hosting an Industry Day for the B-SAFE (Broad-Spectrum Antagonists for Editors) program on June 28, 2024, in Arlington, VA, with a webinar option available. This event is pivotal for those in the science and technology communities, including industry, academia, and government, who are interested in advancing gene editing technologies.

Join DARPA’s B-SAFE Industry Day for Groundbreaking Advances in Gene Editing Inhibitors Read More »

NIH Funding

New NIH Funding Opportunity – Investigating the Role of Genomic Variation on Gene Regulation and Disease

Leave a Comment / EverGlade Insights, NIH / By

At EverGlade Consulting, we are always on the lookout for new funding opportunities that can help our clients advance their research and development goals. Today, we’re excited to inform you about a new Request for Applications (RFA) from the National Institutes of Health (NIH): RFA-HG-24-004.

New NIH Funding Opportunity – Investigating the Role of Genomic Variation on Gene Regulation and Disease Read More »

Futuristic doctor with augmented reality tablet

A Comprehensive Guide to ARPA-H Funding: Process, Financial, and Technical Requirements

Leave a Comment / ARPA-H, Guides / By

The Advanced Research Projects Agency for Health (ARPA-H) stands as a beacon for those within the biomedical and health sectors, propelling transformative research initiatives and breakthroughs. The pursuit of funding from ARPA-H is a monumental stride for entities operating in these domains. This guide endeavors to navigate you through the intricate application process, the financial prerequisites, and the technical stipulations pivotal for securing ARPA-H funding

A Comprehensive Guide to ARPA-H Funding: Process, Financial, and Technical Requirements Read More »

Covid Research

EverGlade Consulting Lands ModeX Therapeutics Up to $168 Million in BARDA Funding

Leave a Comment / BARDA, EverGlade Insights / By

EverGlade Consulting, a national consulting firm, has helped ModeX Therapeutics successfully secure up to $168 million in funding through a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) to develop novel multispecific antibodies against viral infectious disease threats. How Funding Will Be Used The $168 million in BARDA funding will advance research and clinical trials for multispecific

EverGlade Consulting Lands ModeX Therapeutics Up to $168 Million in BARDA Funding Read More »

Scroll to Top
A yellow lab flask with Donald Trump hair and a red tie.

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?

Join us on Jan 15, 2025, at 12:00pm ET for a deep dive into the future of R&D Funding in Life Sciences.

Sign Up